Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of azvudine + tenofovir disoproxil fumarate + efavirenz in treatment-naive HIV infection
ChiCTR2000030780Phase 3Not yet recruiting
- Sponsor
- Beijing YouAn Hospital
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of azvudine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Beijing YouAn Hospital. Primary endpoint: Proportion of subjects with plasma HIV-1 RNA <50 copies/mL at Week 48. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
azvudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ChiCTR2000030780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030780.